Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Picard Medical Inc (PMI)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
$7.17-7.84%
Close 2026-11-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PMI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise capital through equity offerings | A supporting condition in Picard Medical Inc's published investment case. The stated target is Complete $5M capital raise by Q1 2027. | Intact | fails to raise $5M by Q1 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. The company executed a convertible promissory note issuance of $555,555.56 in 2026-Q1 and a registered public offering agreement in 2026-Q2. These capital raising activities align with management's stated focus on strengthening financial resources, showing delivering progress. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a small-cap recovery story, not yet a proven durable compounder. The thesis is in a watch state: revenue and gross profit have improved, while operating losses and compliance and financing concerns remain.
The valuation evidence is mixed and low confidence. PMI is described as cheap versus peers, while another measure shows a 52% premium versus peers and a negative expectations gap; the evidence does not establish a clear market assumption.
Over the recent quarters, revenue rose from $620,000 to $2.95 million, and gross profit moved from negative to positive, but operating losses continue. Near term, capital raising and efforts to regain listing compliance remain important, while the risk label has risen to high and recent filings include negative capital-allocation events.
The multi-year thesis depends on revenue and gross profit gains continuing and translating into better operating performance, alongside progress on listing compliance and financial resources. Near term, weaker employment data could weigh on cyclical healthcare names, while continued strength or weakness from sector bellwethers could either support or weaken the sector backdrop.
PMI shows operating progress, but persistent losses, financing needs, and elevated business risk leave the 1-to-3-year thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Regain compliance with NYSE American listing standards | The company is focused on regaining compliance with NYSE standards. | Improving | fails to meet compliance standards by Q2 2027 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. The company received multiple notices of non-compliance with NYSE American listing standards in 2025-Q4 and 2026-Q1, followed by acceptance of a Compliance Plan in 2026-Q2. The trajectory shows active efforts to regain compliance as management committed. Delivery assessment Oct 31, 2026 |
Increase quarterly revenue to improve financial health | A primary condition in Picard Medical Inc's published investment case. The stated target is >=5.5M. | Intact | falls below 5M in the current fiscal year | Revenue: $2.954M FY2026-Q2; GAAP. Published target: >=5.5M. Target period is not explicitly aligned with this observation. Aug 19, 20262,954,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 6 of last 6 quarters. Revenue grew from $620K in 2025-Q1 to $2.95M in 2026-Q2, and gross profit improved from negative $358K to positive $616K over the same period. Despite improving top-line and gross profit, operating losses remain, indicating progress but continued challenges. Delivery assessment Oct 31, 2026 |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.50 → $-4.50 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-07 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-08 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-09 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-10 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-11 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-12 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-13 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-14 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-15 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-16 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-17 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-18 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-19 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-20 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-21 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-22 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-23 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-24 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-25 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-26 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-27 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-28 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-29 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-09-30 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-01 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-02 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-03 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-04 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-05 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-06 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-07 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-08 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-09 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-10 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-11 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-12 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-13 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-14 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-15 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-16 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-17 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-18 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-19 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-20 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-21 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-22 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-23 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-24 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-25 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-26 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-27 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-28 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-29 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-30 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-10-31 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-11-01 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-11-02 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-11-03 | $-4.50 | $5,900,000 | 1 / 1 |
| 2026-11-04 | $-4.50 | $5,900,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.